Tagrisso has been approved in the United States for adjuvant treatment of adults patients diagnosed early enough for the tumor to be surgically removed, and who have a mutation of the EGFR gene, AstraZeneca said.
AstraZeneca's Tagrisso gets broader US approval for lung cancer
By MAARIV
05/07/2024 03:26 AM
By WALLA!
05/07/2024 02:46 AM
By MAARIV
05/07/2024 01:45 AM
By REUTERS
05/07/2024 01:19 AM
By REUTERS
05/07/2024 01:04 AM
By REUTERS
05/07/2024 12:47 AM
By REUTERS
05/07/2024 12:33 AM
By MAARIV
05/07/2024 12:29 AM
By REUTERS
05/06/2024 06:50 PM